Highly potent fentanyl analogs: apnea from exposure to small quantities of β-hydroxyfentanyl and furanylfentanyl

Robert Hendrickson, Peter Akpunonu, Adrienne R.Hughes, Roy Gerona

Research output: Contribution to journalArticle

Abstract

Context: Fentanyl analogs are synthetic opioids that bind to mu receptors with high potency. We report two cases where users developed apnea and required naloxone reversal after exposure to small quantities of the fentanyl analogs, furanylfentanyl and β-hydroxyfentanyl. Case details: A 19 year-old woman reported insufflating a small number of granules of “fentanyl” powder and developed apnea. A 22 year-old woman touched her tongue to powdered “fentanyl” to treat a migraine headache and became apneic. Results: Furanylfentanyl was identified in the first patient’s serum (3.6 ng/mL furanylfentanyl), urine (17.6 ng/mL furanylfentanyl), and in the product (109mg/g powder). β-hydroxyfentanyl was detected in the second patient’s serum (6.5 ng/mL β-hydroxyfentanyl) and in the product (120 mg/g powder). Discussion: In both cases, furanylfentanyl and β-hydroxyfentanyl were identified in the serum/plasma and urine. Fentanyl analogs were detected in the product at 109-120mg per gram of powder, which suggests that a 500mcg dose of fentanyl analog is the equivalent to 4.17–4.59mg of powder, or about the mass in 1/500th of a packet of sugar. Unique aspects of these cases are the rarely reported use of furanylfentanyl and β-hydroxyfentanyl, intentional insufflation of “fentanyl” for therapeutic and recreational use, the small quantities of powder ingested, and the use of non-targeted analysis to identify the fentanyl analogs.

Original languageEnglish (US)
JournalClinical Toxicology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Fentanyl
Apnea
Powders
Serum
Urine
Insufflation
mu Opioid Receptor
Therapeutic Uses
Naloxone
Migraine Disorders
Tongue
Sugars
Opioid Analgesics
Plasmas

Keywords

  • Beta-hydroxy fentanyl
  • fentanyl
  • furanylfentanyl
  • naloxone
  • respiratory depression

ASJC Scopus subject areas

  • Toxicology

Cite this

Highly potent fentanyl analogs : apnea from exposure to small quantities of β-hydroxyfentanyl and furanylfentanyl. / Hendrickson, Robert; Akpunonu, Peter; R.Hughes, Adrienne; Gerona, Roy.

In: Clinical Toxicology, 01.01.2019.

Research output: Contribution to journalArticle

@article{670b6ec3c25c414281fefbd75d26f890,
title = "Highly potent fentanyl analogs: apnea from exposure to small quantities of β-hydroxyfentanyl and furanylfentanyl",
abstract = "Context: Fentanyl analogs are synthetic opioids that bind to mu receptors with high potency. We report two cases where users developed apnea and required naloxone reversal after exposure to small quantities of the fentanyl analogs, furanylfentanyl and β-hydroxyfentanyl. Case details: A 19 year-old woman reported insufflating a small number of granules of “fentanyl” powder and developed apnea. A 22 year-old woman touched her tongue to powdered “fentanyl” to treat a migraine headache and became apneic. Results: Furanylfentanyl was identified in the first patient’s serum (3.6 ng/mL furanylfentanyl), urine (17.6 ng/mL furanylfentanyl), and in the product (109mg/g powder). β-hydroxyfentanyl was detected in the second patient’s serum (6.5 ng/mL β-hydroxyfentanyl) and in the product (120 mg/g powder). Discussion: In both cases, furanylfentanyl and β-hydroxyfentanyl were identified in the serum/plasma and urine. Fentanyl analogs were detected in the product at 109-120mg per gram of powder, which suggests that a 500mcg dose of fentanyl analog is the equivalent to 4.17–4.59mg of powder, or about the mass in 1/500th of a packet of sugar. Unique aspects of these cases are the rarely reported use of furanylfentanyl and β-hydroxyfentanyl, intentional insufflation of “fentanyl” for therapeutic and recreational use, the small quantities of powder ingested, and the use of non-targeted analysis to identify the fentanyl analogs.",
keywords = "Beta-hydroxy fentanyl, fentanyl, furanylfentanyl, naloxone, respiratory depression",
author = "Robert Hendrickson and Peter Akpunonu and Adrienne R.Hughes and Roy Gerona",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/15563650.2018.1558233",
language = "English (US)",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Highly potent fentanyl analogs

T2 - apnea from exposure to small quantities of β-hydroxyfentanyl and furanylfentanyl

AU - Hendrickson, Robert

AU - Akpunonu, Peter

AU - R.Hughes, Adrienne

AU - Gerona, Roy

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Context: Fentanyl analogs are synthetic opioids that bind to mu receptors with high potency. We report two cases where users developed apnea and required naloxone reversal after exposure to small quantities of the fentanyl analogs, furanylfentanyl and β-hydroxyfentanyl. Case details: A 19 year-old woman reported insufflating a small number of granules of “fentanyl” powder and developed apnea. A 22 year-old woman touched her tongue to powdered “fentanyl” to treat a migraine headache and became apneic. Results: Furanylfentanyl was identified in the first patient’s serum (3.6 ng/mL furanylfentanyl), urine (17.6 ng/mL furanylfentanyl), and in the product (109mg/g powder). β-hydroxyfentanyl was detected in the second patient’s serum (6.5 ng/mL β-hydroxyfentanyl) and in the product (120 mg/g powder). Discussion: In both cases, furanylfentanyl and β-hydroxyfentanyl were identified in the serum/plasma and urine. Fentanyl analogs were detected in the product at 109-120mg per gram of powder, which suggests that a 500mcg dose of fentanyl analog is the equivalent to 4.17–4.59mg of powder, or about the mass in 1/500th of a packet of sugar. Unique aspects of these cases are the rarely reported use of furanylfentanyl and β-hydroxyfentanyl, intentional insufflation of “fentanyl” for therapeutic and recreational use, the small quantities of powder ingested, and the use of non-targeted analysis to identify the fentanyl analogs.

AB - Context: Fentanyl analogs are synthetic opioids that bind to mu receptors with high potency. We report two cases where users developed apnea and required naloxone reversal after exposure to small quantities of the fentanyl analogs, furanylfentanyl and β-hydroxyfentanyl. Case details: A 19 year-old woman reported insufflating a small number of granules of “fentanyl” powder and developed apnea. A 22 year-old woman touched her tongue to powdered “fentanyl” to treat a migraine headache and became apneic. Results: Furanylfentanyl was identified in the first patient’s serum (3.6 ng/mL furanylfentanyl), urine (17.6 ng/mL furanylfentanyl), and in the product (109mg/g powder). β-hydroxyfentanyl was detected in the second patient’s serum (6.5 ng/mL β-hydroxyfentanyl) and in the product (120 mg/g powder). Discussion: In both cases, furanylfentanyl and β-hydroxyfentanyl were identified in the serum/plasma and urine. Fentanyl analogs were detected in the product at 109-120mg per gram of powder, which suggests that a 500mcg dose of fentanyl analog is the equivalent to 4.17–4.59mg of powder, or about the mass in 1/500th of a packet of sugar. Unique aspects of these cases are the rarely reported use of furanylfentanyl and β-hydroxyfentanyl, intentional insufflation of “fentanyl” for therapeutic and recreational use, the small quantities of powder ingested, and the use of non-targeted analysis to identify the fentanyl analogs.

KW - Beta-hydroxy fentanyl

KW - fentanyl

KW - furanylfentanyl

KW - naloxone

KW - respiratory depression

UR - http://www.scopus.com/inward/record.url?scp=85063088893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063088893&partnerID=8YFLogxK

U2 - 10.1080/15563650.2018.1558233

DO - 10.1080/15563650.2018.1558233

M3 - Article

AN - SCOPUS:85063088893

JO - Clinical Toxicology

JF - Clinical Toxicology

SN - 1556-3650

ER -